)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Sartorius Stedim Biotech
Sartorius Stedim Biotech (DIM) investor relations material
Sartorius Stedim Biotech Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary23 Jul, 2026
Executive summary
Achieved solid top-line growth and improved profitability in H1 2026, with strong cash flow generation and continued progress on financial priorities; all regions contributed positively, led by high-margin consumables and services, while equipment stabilized and returned to slight growth.
Underlying EBITDA margin improved to 31.4%–30.3%, with underlying EBITDA up to €479 million and net profit rising 17.6% to €181 million.
Free cash flow rose sharply, up over 70% to €208 million or nearly doubled to €199 million; deleveraging remains on track.
Management confirmed full-year 2026 guidance and introduced new mid-term targets for sustainable growth above market levels.
Received substantial U.S. tariff refunds, with customer compensation for surcharges impacting reported results.
Financial highlights
Group sales revenue increased by 7.7% operationally in constant currencies (up to €1,811 million), with reported growth of 2.5%–6.4% due to tariff-related effects.
Underlying EBITDA margin improved to 31.4%–30.3%; underlying net profit increased by 2% to €172 million, reported net profit up nearly 51% to €122 million or 17.6% to €181 million.
Free cash flow rose by over 70% to €208 million; operating cash flow up 25%–39.4% to €364 million or €341 million.
CapEx ratio at 8.9%–9.3%, with full-year expectation of around 12.5%.
Outlook and guidance
Full-year group sales revenue growth expected at 5%–10% in constant currencies; underlying EBITDA margin forecast slightly above 30%–31%.
BPS guidance: 6%–10% growth; LPS: 2%–6%, with MatTek contributing up to 2.8 percentage points.
CapEx ratio to remain at prior year level; net debt to underlying EBITDA expected slightly above 2–3x at year-end.
FX headwinds and tariff compensation expected to reduce reported revenue growth by about 2 percentage points or up to €35 million.
New mid-term targets: organic sales revenue growth of 9%–12% per year and EBITDA margin expansion of 60–85 bps annually from 2027 onward.
Revenue impact of customer tariff compensation
Margin impact of product mix vs scale effects
Sustainability of China recovery in Asia / Pacific
Impact of U.S. tariff refunds on H1 2026 results
China recovery impact on Asia Pacific H1 growth
Mid-term market outperformance targets from 2027
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sartorius Stedim Biotech
- Strong H1 2025 growth in sales and margins, led by consumables; guidance reaffirmed.DIM
Q2 20259 Jul 2026 - Exceeded 2025 guidance with strong consumables growth; 2026 outlook sees margin expansion.DIMQ4 20258 Jul 2026
- Sales and profit declined, outlook revised down amid volatility and regional weakness.DIMQ2 20248 Jul 2026
- 2024 guidance met with strong cash flow, robust margins, and moderate growth expected for 2025.DIMQ4 20248 Jul 2026
- Q1 2026 delivered strong sales and cash flow growth, with guidance reaffirmed amid volatility.DIMQ1 202626 Apr 2026
- All resolutions passed as strong financial results and strategic growth plans were presented.DIMAGM 202626 Mar 2026
- Targets 9–12% organic sales growth and margin expansion, fueled by innovation and efficiency.DIMCMD 202617 Mar 2026
- Order intake and recurring business drove stable results and margins, with guidance confirmed.DIMQ3 202419 Jan 2026
- All resolutions passed amid strong 2024 results, global expansion, and innovation focus.DIMAGM 20253 Dec 2025
Next Sartorius Stedim Biotech earnings date
Q3 202622 Oct, 2026
Sartorius Stedim Biotech
Next Sartorius Stedim Biotech earnings date
Q3 202622 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage